Equities research analysts expect that Heska Corp (NASDAQ:HSKA) will post $0.17 earnings per share (EPS) for the current quarter, according to Zacks. Two analysts have issued estimates for Heska’s earnings. The lowest EPS estimate is $0.16 and the highest is $0.17. Heska reported earnings per share of $0.44 in the same quarter last year, which would suggest a negative year over year growth rate of 61.4%. The company is scheduled to announce its next earnings report on Monday, July 30th.
On average, analysts expect that Heska will report full-year earnings of $1.68 per share for the current year, with EPS estimates ranging from $1.63 to $1.73. For the next financial year, analysts expect that the business will post earnings of $2.07 per share, with EPS estimates ranging from $2.03 to $2.11. Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research analysts that follow Heska.
Heska (NASDAQ:HSKA) last announced its earnings results on Friday, May 4th. The medical research company reported $0.28 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.40 by ($0.12). The firm had revenue of $32.77 million for the quarter, compared to analyst estimates of $31.65 million. Heska had a return on equity of 13.30% and a net margin of 5.57%.
In other Heska news, Director Bonnie J. Trowbridge sold 5,000 shares of the firm’s stock in a transaction dated Tuesday, May 29th. The shares were sold at an average price of $101.01, for a total value of $505,050.00. Following the completion of the sale, the director now owns 6,249 shares in the company, valued at approximately $631,211.49. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, COO Jason A. Napolitano sold 5,502 shares of Heska stock in a transaction that occurred on Thursday, May 31st. The stock was sold at an average price of $106.08, for a total transaction of $583,652.16. The disclosure for this sale can be found here. Insiders sold a total of 26,202 shares of company stock valued at $2,752,523 in the last 90 days. Corporate insiders own 15.90% of the company’s stock.
Several large investors have recently modified their holdings of HSKA. Schwab Charles Investment Management Inc. grew its position in shares of Heska by 7.3% during the 4th quarter. Schwab Charles Investment Management Inc. now owns 33,502 shares of the medical research company’s stock worth $2,688,000 after buying an additional 2,287 shares during the period. Quantitative Systematic Strategies LLC acquired a new stake in shares of Heska during the 4th quarter worth approximately $206,000. Cadence Capital Management LLC grew its position in shares of Heska by 7.7% during the 4th quarter. Cadence Capital Management LLC now owns 16,009 shares of the medical research company’s stock worth $1,284,000 after buying an additional 1,150 shares during the period. Arizona State Retirement System grew its position in shares of Heska by 226.1% during the 4th quarter. Arizona State Retirement System now owns 10,958 shares of the medical research company’s stock worth $879,000 after buying an additional 7,598 shares during the period. Finally, Rhumbline Advisers grew its position in shares of Heska by 13.3% during the 4th quarter. Rhumbline Advisers now owns 14,785 shares of the medical research company’s stock worth $1,186,000 after buying an additional 1,731 shares during the period. Institutional investors own 89.19% of the company’s stock.
Shares of Heska traded down $0.15, reaching $106.75, during mid-day trading on Friday, MarketBeat Ratings reports. 100,100 shares of the stock were exchanged, compared to its average volume of 90,309. The stock has a market capitalization of $794.07 million, a P/E ratio of 51.57 and a beta of 0.80. Heska has a fifty-two week low of $56.59 and a fifty-two week high of $115.00.
Heska Company Profile
Heska Corporation manufactures, sells, and markets veterinary diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Europe, and internationally. The company's Core Companion Animal Health segment offers Element DC and DRI-CHEM 7000 veterinary chemistry analyzers for blood chemistry and electrolyte analysis; HT5 and HEMATRUE veterinary hematology analyzers to measure blood cell and platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; COAG veterinary analyzers; Element i immunodiagnostic analyzers; and IV infusion pumps.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Heska Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska and related companies with MarketBeat.com's FREE daily email newsletter.